Robert Ivy: Architecture for a Healthy Future

     Robert Ivy has been the Executive Vice President and Chief Executive Officer of the American Institute of Architects since February of 2011. The American Institute of Architects has almost 88,000 members as of today. Robert Ivy is leading the AIA into the future by making the organization more relevant to modern day and more valuable as he hopes to improve the lives of the people in the United States through architecture and design. He was named a Master Architect in 2010 by Alpha Rho Chi.

Studies have already shown that proper design can improve health care making it so sick people are able to get better faster, or at least be more comfortable. Robert Ivy believes that design can prevent healthy people from getting sick as well.

When most people think about public health, they don’t often think about architecture. Architecture can encourage a more active lifestyle and create a healthier environment by using safe materials. Many cities are trying to implement more green space into their plans to provide safe and attractive parks for residents to walk in, both for leisure and to get to their destination without the aid of vehicles. Schools are also being built to use more natural lighting in order to help students concentrate and stay awake during class. Hospitals are being designed so patients can engage in more physical activity during recovery instead of being confined to cramped hallways filled with medical equipment.

Robert Ivy was born in Columbus, Mississippi. At the University of the South in Tenessee, Ivy graduated Cum Laude in English with a bachelor’s degree in 1969. In 1973 he continued his education at Tulane University where he was an honorary member of the Tau Sigma Delta architectural fraternity until 1976. He graduated in 1976 with a master’s degree in Architecture.

Robert Ivy believes the future of architecture is in designing for a lower impact on the environment, sustainability, and better health. Urban living can reduce the carbon footprint created by people. By creating sustainable architecture, we not only prevent waste but can also build so the buildings can withstand disasters whether they be natural or manmade. When human lives are at stake, whether it be in the long-term or short-term, it’s vital that we see safety and health as equally if not more important than aesthetics. The two can be combined to create a visually pleasing and healthy future for everyone.

Amicus Therapeutics leads in the treatment of lysosomal storage disorders.

Amicus Therapeutics Biopharmaceutical Company is located in Cranbury, New Jersey. However, in 2008 it grew into a larger firm and expanded from its original set up in Cranbury to a second research site in San Diego. The company was established by major investors including Canaan Partners, Radius Ventures, and New Enterprise Associates.The company`s therapeutical products development relies on the Chaperone Advanced Replacement Therapy (CHART) technology. It has also focused on the development of enzyme replacement therapies (ERTs).


Amicus Therapeutics establishes and develops drugs and medicines that treat lysosomal storage disorders, a rare disease. Unlike other types of treatments which focus on replacing defective enzymes, Amicus Therapeutics uses the small molecule pharmacological chaperones which bind to a victim`s defective proteins and help to restore their functions and activities in the body. In 2014 Amicus Therapeutics Biopharmaceutical Company had the extensive portfolio of small molecule pharmacological chaperones among all other pharmaceutical firms.


In 2014 they developed Migalastat, an advanced pharmacological chaperone for treating Fabry disease. The main aim of the product is to stabilize endogenous mutant alpha-galactosidase. In 2013 Amicus Therapeutics established enzyme replacement therapy for the treatment of a rare disease known as Pombe by use of candidate AT2220. They also developed another candidate, Plicera for the treatment of Gaucher disease.


Amicus Therapeutics Company used to rely on contract manufacturing alone since they had no capability and adequate resources to stand on their own (YahooFinance). It made the company fall into a financial crisis after termination of the collaboration agreement with The Shire in 2009. However, in 2010 Amicus Therapeutics received the grant worth $ 210, 300 from the Alzheimer`s Drug Discovery Foundation. By the end of the year 2015, the Amicus Therapeutics had acquired Scioderm for over $ 947 million in both cash and stock.


The Amicus Therapeutics biopharmaceutical firm has become a leading business and science driven in delivering meaningful benefits and healthcare to their patients globally. The company`s product pipeline and technology platform put in place positions the qualified and experienced staffs at the forefront of developing therapies to meet significant unmet needs for rare and orphan diseases. The company through research is determined to develop drugs for neurodegenerative diseases including Parkinson`s and Alzheimer`s.

More about Amicus Therapeutics on :,-NJ-jobs.html